^
Association details:
Biomarker:HRAS G13R
Cancer:Thyroid Gland Carcinoma
Drug:Mekinist (trametinib) (MEK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

The Mitogen Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor, Dasatinib, in Thyroid Cancer

Excerpt:
Human thyroid cancer cell lines C643, SW1736, BCPAP, and Cal62 were grown in RPMI....MEK1/2 inhibition with trametinib effectively inhibited growth in all four control and DasRes cell lines, with IC50s between 0.01 and 1 μM, with the RAS-mutant, C643, cell line exhibiting enhanced sensitivity in the DasRes line over the control (Fig. 4A and Table S3)....SRB growth analysis of the BCPAP, SW1736, C643, and Cal62 control and DasRes cell lines in response to indicated concentrations of trametinib (μM) for 72 hours. B. & C.) Western blot analysis on BRAF-mutant (B.) BCPAP, SW1736, and RAS-mutant (C.)
DOI:
10.1158/1535-7163.MCT-15-0702